Xagena.net - Update in Medicine

The FDA ( U.S. Food and Drug Administration ) has approved Dupixent ( Dupilumab ) to treat adults with nasal polyps accompanied by chronic rhinosinusitis ( prolonged inflammation of the sinuses and nasal cavity ).
This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.

Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps.
Dupixent provides an important treatment option for patients whose nasal polyps are not adequately controlled with intranasal steroids. It also reduces the need for nasal polyp surgery and oral steroids.

Dupixent is given by injection. The efficacy and safety of Dupixent were established in two studies with 724 patients, 18 years and older with chronic rhinosinusitis with nasal polyps who were symptomatic despite taking intranasal corticosteroids.
Patients who received Dupixent had statistically significant reductions in their nasal polyp size and nasal congestion compared to the placebo group.
Patients taking Dupixent also reported an increased ability to smell and required less nasal polyp surgery and oral steroids.

Dupixent may cause serious allergic reactions and eye problems, such as inflammation of the eye ( conjunctivitis ) and inflammation of the cornea ( keratitis ).
If patients experience new or worsening eye symptoms, such as redness, itching, pain or visual changes, they should consult their health care professional.
The most common side effects reported include injection site reactions as well as eye and eyelid inflammation, which included redness, swelling and itching.

Patients receiving Dupixent should avoid receiving live vaccines.

Dupixent was originally approved in 2017 for patients 12 and older with eczema that is not controlled adequately by topical therapies or when those therapies are not advisable.
In 2018, Dupixent was approved as an add-on maintenance treatment for patients 12 years and older with moderate-to-severe eosinophilic asthma or with oral corticosteroid-dependent asthma. ( Xagena )

Source: FDA, 2019